Biologics are the latest treatment used in clinical studies, particularly in orthopedic surgery. Spine biologics are biomaterials that alter the surroundings through their active cellular processes that promote growth and differentiation, thereby assisting in the repair and healing of the injury or any condition. Some biologics are designed to be used as replacements for a person's natural bone graft, while other biologics that promote cartilaginous and bony structure’s repair & regeneration are currently in their developmental stage.
Global Spine Biologics Market – Dynamics
Recent product launches are expected to boost global spine biologics market growth. For instance, on January 9, 2020, Royal Biologics, a company, which produces orthobiologics and is dedicated in the research and advancement of regenerative cellular therapy & novel orthobiologic solutions, announced the launch of MAGNUS, a DMSO-free viable cellular bone allograft. Due to the use of DMSO-free cryoprotectant, MAGNUS offers a novel alternative to traditional viable cellular allograft technology.
Moreover, rising mergers, agreements, and acquisitions by market players are also expected to drive the global spine biologics market over the forecast period. For instance, on April 27, 2021, Bone Bank Allografts (BBA), a leading provider of regenerative medicine technologies, announced their multi-year supplier partnership agreement with Capstone Health Alliance, a regional group purchasing organization (GPO) with 300 hospitals representing 140 health systems across the U.S. The agreement covers BBA's entire orthobiologics portfolio, which includes surgical allograft options ranging from traditional bone and soft tissues to specialty custom products for transplant. These factors are expected to support global spine biologics market growth over the forecast period.
Global Spine Biologics Market – Regional Insights
North America is expected to dominate the global spine biologics market, owing to the continuous registrations and approvals of spine biologics by the U.S. Food and Drug Administration (FDA). For instance, on February 25, 2020, EmCyte, one of the global leaders in platelet rich plasma and progenitor stem cell biologics, received FDA 510 (k) clearance for its PurePRP SupraPhysiologic Concentrating System for platelet rich plasma.
Furthermore, Europe region is expected to witness a significant growth in the forecast period, due to emerging cases of spinal cord injury (SCI) and spine muscular atrophy, thereby increasing the need for spine biologics-based therapies. For instance, according to National Health Service (NHS), UK, in England in 2017-18, there were approximately 1200 new spinal cord injury cases that required admission of the patients into a spinal cord injury center. In addition, in 2019, 600 children and 1,200 adults were reported to have spine muscular atrophy in England and Wales. These factors are expected to support global spine biologics market growth over the forecast period.
Global Spine Biologics Market – Taxonomy
By Product type:
- Bone Graft
- Bone Graft Substitute
- Platelet Rich Plasma (PRP)
- Bone Marrow Aspirate Concentrate (BMAC)
By Surgery Type:
- Anterior Cervical Discectomy and Fusion
- Posterior Lumbar Interbody Fusion
- Transforaminal Lumbar Interbody Fusion (TLIF)
- Anterior Lumbar Interbody Fusion (ALIF)
- Lateral Lumbar Interbody Fusion (LLIF)
By End User:
- Orthopedic clinics
- Ambulatory surgical centers
- North America
- Asia Pacific
- Latin America
- Middle East
Global Spine Biologics Market – Competitive landscape
Key players involved in the global spine biologics market include Fuse Medical Inc., Medtronic plc., Zimmer Biomet, Wright Medical Group Inc., NuVasive Inc., Stryker Corporation, EmCyte Corporation, OrthoPediatrics Corp., Baxter International, HemaCare Corporation, K2M Inc., Adimarket, LLC, and Orthofix Medical Inc.